Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
A recent study found that 30% of patients stopped within four weeks, and less than half stayed on the medication for 12 weeks or more
Foviscu (WCK 4282) - Phase 3 Ongoing First-line empiric treatment for gram-negative hospital infections (cUTI, HABP/VABP) Complements ZAYNICH: while ZAYNICH is the destination therapy at the top of the pyramid for resistant infections, Foviscu is the entry-level, broad-use first drug of choice Global Phase 3 trial underway If approved, the commercial TAM is significantly larger than ZAYNICH due to broader use 5
And because cyclic AMP responses are fast and transient, the timing of your measurement matters as much as the concentration
When you add these foods to your meals, you help your body defend itself and stay well
)
US$ 28.55
US$ 23.47
)
US$ 27.38
)
US$ 27.93
US$ 21.57
